I just merged the two Karuna threads.
Whatâs the name of the drug they are developing?
edit: ok KarXT I saw it now.
1 Like
So karxt is two meds xanomeline and trospium. Trospium is already out and its apparently used to help with bladder control? Apparently the xanomeline causes some side effects related to the bladder or something like that so they want people taking trospium at the same time.
I dont fully understand what xanomeline does as its an muscarinic agonist. Says it agonizes m1-m4 and partial agonist of the other muscarinic receptors. Im a little confused as to what this receptor does exactly. But it says it effects the central nervous system.
1 Like
I didnât know that. Thatâs a downer.
My med i take right now has been the best thing that has ever happened to me and i get little bad effects, i am very grateful for what i have got and idk if anything could do a better job, i really hope this drug helps a lot of people though,
Its very strange how it doesnât affect the dopamine/seratonin bc that has always been the way its been done, i have never heard of this new pathway in the brain, hopefully the side effects are not too bad.
If you read carefully it says doesnât affect dopamine directly but according to Wikipedia and muscarinic receptors function, it does affect dopamine indirectly.
As if its good for negatives will depend on where in the brain it will act but I think like all other APs it will act on all the brain.
Yeah im reading and it agonizes all muscarinic receptors m1 m2 m3 m4 m5. Partial agonist of m2 m3 m5.
This other drug called emraclidine sounds a lot better as apparently it only agonizes the m4 receptor. However that drug wont be approved until like 2032.
1 Like
I would say âitâs hard to overstateâ, not âhard to understateâ ))
I previously came across KarXT in a 2021 review article, and thought it had been prevented from entry into the market due to side effects. Quote:
In 2018, Karuna therapeutics created âKarXT â, a combination therapy of xanomeline and trospium (a peripherally restricted mAChR antagonist) (Brannan et al., 2020). In KarXT, trospium specifically blocks the peripheral actions of xanomeline, while allowing xanomeline to provide therapeutic efficacy in the CNS. In phase IIb clinical trials, KarXT successfully reduced positive, negative and cognitive symptoms in schizophrenic patients, but some anti-muscarinic side effects such as constipation, nausea, dry mouth, dyspepsia and vomiting were still observed (Brannan et al., 2020).
Becoming someones â â â â â is easier said than done. If you are cured would you really pay up for life or would you suddenly see it as unfair.
Me coming from the hard sciences I see all these statistical investigations more like doing the homework and paying the money and less like research.
This is good news. Thank you for posting.
2 Likes